Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone liposome + venetoclax + azacitidine for newly diagnosed and relapsed/refractory AML
ChiCTR2400091259Phase 4Not yet recruiting
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Oct 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mitoxantrone, venetoclax and azacitidine in acute myeloid leukemia (AML), sponsored by General Hospital of the Northern Theater Command. Primary endpoint: Composite complete remission rate (CRc). Planned start Oct 2024; status: not yet recruiting.
02
Drugs
mitoxantronevenetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2400091259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091259.